**Callitas Health Announces the Promotion of Joshua Maurice to Vice President of Sales and Business Development**

**CINCINNATI, OH,** March 12, 2019 – [Callitas Health Inc.](https://callitas.com/), (CSE: LILY, OTCQB: MPHMF, FWB: T3F3), (the “Company” or “Callitas”) a clinical-stage pharmaceutical development, OTC consumer goods marketing and cannabis delivery development company, today announced that Joshua Maurice has been promoted to vice president of sales and business development for Callitas, effective March 12, 2019.

Callitas continues to develop and expand its management team and personnel and bring in new consultants to capitalize on the progress the Company has made in 2019 and to keep up with the existing and new advancements and partnerships.

“We are proud to announce Joshua’s promotion to vice president of sales and business development” said James Thompson, Callitas president and chief executive officer. “Joshua has been an effective and strategic leader within Callitas. His skills, expertise and strong business acumen have contributed to the solid execution of our sales and marketing strategies and growth in our partner relationships. Supported by talented and dedicated associates, Joshua will continue to play a key role in the success of our Company.”

“We’ve seen important strides in the first months of 2019 across the women’s health, cannabinoid and infertility spaces and deepening partnerships with companies like NFI Consumer Healthcare and Lifestyles,” added Mr.Thompson. “Promoting Joshua to this new position allows us to utilize his talents to further capitalize on these advancements in the Company.”

“I’m excited to move into this new role at Callitas, especially given the many positive initiatives underway and planned for 2019,” said Maurice. “We have many important projects in our pipeline and we expect many of these will mature to become significant contributors to our growth in the near future.”

**About Callitas Health**

Callitas Health Inc. is a clinical-stage pharmaceutical development, OTC consumer goods marketing and cannabis delivery development company, focused on developing innovative technologies for weight management, female sexual health and wellness, cannabis delivery technologies and other proprietary drugs. For more information, visit [www.callitas.com](http://www.callitas.com).

**For more information contact**

Callitas Health

James Thompson, CEO, or

Callitas Investor Relations

T 859-868-3131

TraDigitalIR

Investor Relations – Kevin McGrath, Managing Director

T 646-418-7002

**Notice regarding Forward Looking Statements:** This news release contains forward-looking statements. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. This news release includes forward-looking statements with respect to the regulatory approval and the commercialization of the rights to the Company’s biomedical & drug technologies. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this news release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile on www.sedar.com and the Company’s filings to the CSE at www.thecse.com. Such risk factors may cause the inability of the Company to successfully commercialize any of its biomedical technologies.

**Notice regarding investigational devices:** CannaMint Strips, C-103 and Extrinsa are investigational drugs or devices and are not currently available outside of approved clinical trials. Claims regarding the safety and efficacy of these devices have not been evaluated by Health Canada, the U.S. Food and Drug Administration, or any other international regulatory body. Neither the Canadian Securities Exchange nor its Regulation Service Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

**Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:** Statements in this press release that are not strictly historical are “forward-looking” statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. These statements involve a high degree of risk and uncertainty, are predictions only and actual events or results may differ materially from those projected in such forward-looking statements.